呼吸器ウイルスワクチンの世界市場2020-2030：種類別（不活化/死菌ワクチン、弱毒生ワクチン、組換えワクチン）、投与経路別、疾患別、年齢層別、エンドユーザー別

• 英文タイトル：Respiratory Virus Vaccines Market (Type: Inactivated/Killed Vaccines, Live-attenuated Vaccines, and Recombinant Vaccines; Route of Administration: Intramuscular, Intranasal, and Subcutaneous; Indication: Influenza, Measles, Mumps & Rubella, Coronavirus Disease [COVID-19], and Others; Age Group: Pediatric and Adults; and End User: Physician’s Office, Hospitals, Clinics, and Pharmacies/Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030

• レポートコード：TMR2010020 • 出版社/出版日：Transparency Market Research / 2020年8月17日 • レポート形態：英文、PDF、193ページ • 納品方法：Eメール • 産業分類：製薬

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Global Site License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートは、呼吸器ウイルスワクチンの世界市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、市場展望、種類別（不活化/死菌ワクチン、弱毒生ワクチン、組換えワクチン）分析、投与経路別分析、疾患別分析、年齢層別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・市場展望 ・呼吸器ウイルスワクチンの世界市場規模：種類別（不活化/死菌ワクチン、弱毒生ワクチン、組換えワクチン） ・呼吸器ウイルスワクチンの世界市場規模：投与経路別 ・呼吸器ウイルスワクチンの世界市場規模：疾患別 ・呼吸器ウイルスワクチンの世界市場規模：年齢層別 ・呼吸器ウイルスワクチンの世界市場規模：エンドユーザー別 ・呼吸器ウイルスワクチンの世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ） ・競争状況

Respiratory Virus Vaccines Market – Scope of the Report

TMR’s report on the global respiratory virus vaccines market studies the past as well as current growth trends and opportunities to gain valuable insights for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global respiratory virus vaccines market for period from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) for the global respiratory virus vaccines market for the same period.

The report has been prepared after extensive research. Primary research involves bulk of research efforts, wherein analysts conducted interviews with market leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus vaccines market.

Secondary research also includes Internet sources and statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the global respiratory virus vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various market segments included in the scope of the study. Furthermore, the report sheds light on the changing competition dynamics in the global respiratory virus vaccines market. These indices serve as valuable tools for existing market players as well as new players interested in entering the global respiratory virus vaccines market. The next section of the report highlights the USPs, which include pipeline analysis, disease prevalence & incidence rate globally with key countries, key industry events (mergers, acquisitions, collaborations, approvals, etc.) and COVID-19 pandemic impact on industry (value chain and short-/mid-/ long-term impact).

The report delves into the competitive landscape of the global respiratory virus vaccines market. Key players operating in the global respiratory virus vaccines market have been identified and each one of them has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players operating in the global respiratory virus vaccines market profiled in this report.

Key Questions Answered in Respiratory Virus Vaccines Market Report

What are the major drivers, restraints, and opportunities in the global respiratory virus vaccines market?
What is the revenue share projection of key segments of the global respiratory virus vaccines market during the forecast period?
Which segment is likely to lead the global respiratory virus vaccines market in terms of revenue between 2020 and 2030?
How mergers & acquisitions among players are widening the scope of the global respiratory virus vaccines market?
What is the market position of different companies operating in the global respiratory virus vaccines market?
Respiratory Virus Vaccines Market – Research Objectives and Research Approach

The comprehensive report on the global respiratory virus vaccines market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global respiratory virus vaccines market. It is followed by market introduction, market dynamics, and an overview of the global respiratory virus vaccines market, which includes TMR’s analysis of market drivers, restraints, and trends pertaining to the global respiratory virus vaccines market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global respiratory virus vaccines market. The next section of the global respiratory virus vaccines report highlights the USPs, which include pipeline analysis, disease prevalence & incidence rate globally with key countries, key industry events (mergers, acquisitions, collaborations, approvals, etc.) and COVID-19 pandemic impact on industry (value chain and short-/mid-/long-term impact).

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report segments the global respiratory virus vaccines market in terms of type, route of administration, indication, age group, end user, and region. Key segments under each criterion have been studied at length and the market share for each segment by the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investments in the global respiratory virus vaccines market.

レポート目次

---

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Virus Vaccines Market

4. Market Overview

4.1. Introduction

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Respiratory Virus Vaccines Market Analysis and Forecast, 2018–2030

5. Market Outlook

5.1. Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.)

5.2. Disease Prevalence & Incidence Rate globally with key countries

5.3. Pipeline Analysis

5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact) Pricing Analysis

6. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type

6.1. Introduction & Definition

6.2. Global Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

6.2.1. Inactivated/Killed Vaccines

6.2.2. Live-attenuated Vaccines

6.2.3. Recombinant vaccines

6.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type

7. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration

7.1. Introduction & Definition

7.2. Global Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

7.2.1. Intramuscular

7.2.2. Intranasal

7.2.3. Subcutaneous

7.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration

8. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication

8.1. Global Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

8.1.1. Influenza

8.1.2. Measles, Mumps & Rubella

8.1.3. Coronavirus Disease (COVID-19)

8.1.4. Others

8.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication

9. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group

9.1. Global Respiratory Virus Vaccines Market Value Forecast, by Age Group, 2018–2030

9.1.1. Pediatric

9.1.2. Adults

9.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group

10. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user

10.1. Global Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

10.1.1. Physician’s Office

10.1.2. Hospitals

10.1.3. Clinics

10.1.4. Pharmacy/Store

10.1.5. Others

10.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user

11. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region

11.1. Introduction

11.2. Global Respiratory Virus Vaccines Market Value Forecast, by Region, 2018–2030

11.2.1. North America

11.2.2. Europe

11.2.3. Asia Pacific

11.2.4. Latin America

11.2.5. Middle East & Africa

11.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region

12. North America Respiratory Virus Vaccines Market Analysis and Forecast

12.1. Introduction

12.2. North America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

12.2.1. Inactivated/Killed Vaccines

12.2.2. Live-attenuated Vaccines

12.2.3. Recombinant vaccines

12.3. North America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

12.3.1. Intramuscular

12.3.2. Intranasal

12.3.3. Subcutaneous

12.4. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

12.4.1. Influenza

12.4.2. Measles, Mumps & Rubella

12.4.3. Coronavirus Disease (COVID-19)

12.4.4. Others

12.5. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

12.5.1. Pediatric

12.5.2. Adults

12.6. North America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

12.6.1. Physician Offices

12.6.2. Hospitals

12.6.3. Clinics

12.6.4. Pharmacy/Store

12.6.5. Others

12.7. North America Respiratory Virus Vaccines Market Value Forecast, by Country, 2018–2030

12.7.1. U.S.

12.7.2. Canada

12.8. North America Respiratory Virus Vaccines Market Attractiveness Analysis

12.8.1. By Type

12.8.2. By Route of Administration

12.8.3. By Indication

12.8.4. By Age Group

12.8.5. By End-user

12.8.6. By Country

13. Europe Respiratory Virus Vaccines Market Analysis and Forecast

13.1. Introduction

13.2. Europe Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

13.2.1. Inactivated/Killed Vaccines

13.2.2. Live-attenuated Vaccines

13.2.3. Recombinant vaccines

13.3. Europe Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

13.3.1. Intramuscular

13.3.2. Intranasal

13.3.3. Subcutaneous

13.4. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

13.4.1. Influenza

13.4.2. Measles, Mumps & Rubella

13.4.3. Coronavirus Disease (COVID-19)

13.4.4. Others

13.5. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

13.5.1. Pediatric

13.5.2. Adults

13.6. Europe Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

13.6.1. Physician Offices

13.6.2. Hospitals

13.6.3. Clinics

13.6.4. Pharmacy/Store

13.6.5. Others

13.7. Europe Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

13.7.1. Germany

13.7.2. U.K.

13.7.3. France

13.7.4. Spain

13.7.5. Italy

13.7.6. Rest of Europe

13.8. Europe Respiratory Virus Vaccines Market Attractiveness Analysis

13.8.1. By Type

13.8.2. By Route of Administration

13.8.3. By Indication

13.8.4. By Age Group

13.8.5. By End-user

13.8.6. By Country/Sub-region

14. Asia Pacific Respiratory Virus Vaccines Market Analysis and Forecast

14.1. Introduction

14.2. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

14.2.1. Inactivated/Killed Vaccines

14.2.2. Live-attenuated Vaccines

14.2.3. Recombinant vaccines

14.3. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

14.3.1. Intramuscular

14.3.2. Intranasal

14.3.3. Subcutaneous

14.4. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

14.4.1. Influenza

14.4.2. Measles, Mumps & Rubella

14.4.3. Coronavirus Disease (COVID-19)

14.4.4. Others

14.5. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

14.5.1. Pediatric

14.5.2. Adults

14.6. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

14.6.1. Physician Offices

14.6.2. Hospitals

14.6.3. Clinics

14.6.4. Pharmacy/Store

14.6.5. Others

14.7. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

14.7.1. Japan

14.7.2. China

14.7.3. India

14.7.4. Australia & New Zealand

14.7.5. Rest of Asia Pacific

14.8. Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis

14.8.1. By Type

14.8.2. By Route of Administration

14.8.3. By Indication

14.8.4. By Age Group

14.8.5. By End-user

14.8.6. By Country/Sub-region

15. Latin America Respiratory Virus Vaccines Market Analysis and Forecast

15.1. Introduction

15.2. Latin America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

15.2.1. Inactivated/Killed Vaccines

15.2.2. Live-attenuated Vaccines

15.2.3. Recombinant vaccines

15.3. Latin America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

15.3.1. Intramuscular

15.3.2. Intranasal

15.3.3. Subcutaneous

15.4. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

15.4.1. Influenza

15.4.2. Measles, Mumps & Rubella

15.4.3. Coronavirus Disease (COVID-19)

15.4.4. Others

15.5. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

15.5.1. Pediatric

15.5.2. Adults

15.6. Latin America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

15.6.1. Physician Offices

15.6.2. Hospitals

15.6.3. Clinics

15.6.4. Pharmacy/Store

15.6.5. Others

15.7. Latin America Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

15.7.1. Brazil

15.7.2. Mexico

15.7.3. Rest of Latin America

15.8. Latin America Respiratory Virus Vaccines Market Attractiveness Analysis

15.8.1. By Type

15.8.2. By Route of Administration

15.8.3. By Indication

15.8.4. By Age Group

15.8.5. By End-user

15.8.6. By Country/Sub-region

16. Middle East & Africa Respiratory Virus Vaccines Market Analysis and Forecast

16.1. Introduction

16.2. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

16.2.1. Inactivated/Killed Vaccines

16.2.2. Live-attenuated Vaccines

16.2.3. Recombinant vaccines

16.3. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Route of Administration , 2018–2030

16.3.1. Intramuscular

16.3.2. Intranasal

16.3.3. Subcutaneous

16.4. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

16.4.1. Influenza

16.4.2. Measles, Mumps & Rubella

16.4.3. Coronavirus Disease (COVID-19)

16.4.4. Others

16.5. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

16.5.1. Pediatric

16.5.2. Adults

16.6. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

16.6.1. Physician Offices

16.6.2. Hospitals

16.6.3. Clinics

16.6.4. Pharmacy/Store

16.6.5. Others

16.7. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

16.7.1. GCC Countries

16.7.2. South Africa

16.7.3. Rest of Middle East & Africa

16.8. Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis

16.8.1. By Type

16.8.2. By Route of Administration

16.8.3. By Indication

16.8.4. By Age Group

16.8.5. By End-user

16.8.6. By Country/Sub-region

17. Competition Landscape

17.1. Market Player – Competition Matrix (by tier and size of companies)

17.2. Global Respiratory Virus Vaccines Market Position Analysis, by Company, 2019

17.3. Company Profiles

17.3.1. CSL Limited

17.3.1.1. Company Description

17.3.1.2. Business Overview

17.3.1.3. Financial Overview

17.3.1.4. Strategic Overview

17.3.1.5. SWOT Analysis

17.3.2. Sanofi

17.3.2.1. Company Description

17.3.2.2. Business Overview

17.3.2.3. Financial Overview

17.3.2.4. Strategic Overview

17.3.2.5. SWOT Analysis

17.3.3. AstraZeneca

17.3.3.1. Company Description

17.3.3.2. Business Overview

17.3.3.3. Financial Overview

17.3.3.4. Strategic Overview

17.3.3.5. SWOT Analysis

17.3.4. Merck & Co., Inc.

17.3.4.1. Company Description

17.3.4.2. Business Overview

17.3.4.3. Strategic Overview

17.3.4.4. Financial Overview

17.3.4.5. SWOT Analysis

17.3.5. GlaxoSmithKline plc

17.3.5.1. Company Description

17.3.5.2. Business Overview

17.3.5.3. Strategic Overview

17.3.5.4. Financial Overview

17.3.5.5. SWOT Analysis

17.3.6. Serum Institute of India Pvt. Ltd.

17.3.6.1. Company Description

17.3.6.2. Business Overview

17.3.6.3. Financial Overview

17.3.6.4. Strategic Overview

17.3.6.5. SWOT Analysis

17.3.7. Bharat Biotech

17.3.7.1. Company Description

17.3.7.2. Business Overview

17.3.7.3. Financial Overview

17.3.7.4. Strategic Overview

17.3.7.5. SWOT Analysis

17.3.8. Sinovac Biotech Ltd.

17.3.8.1. Company Description

17.3.8.2. Business Overview

17.3.8.3. Financial Overview

17.3.8.4. Strategic Overview

17.3.8.5. SWOT Analysis

List of Tables:

Table 01 Pipeline Analysis (1/4)

Table 02 Pipeline Analysis (2/4)

Table 03 Pipeline Analysis (3/4)

Table 04 Pipeline Analysis (4/4)

Table 05 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (1/3)

Table 06 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (2/3)

Table 07 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (3/3)

Table 08 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 12 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 13 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 14 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 15 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 16 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 18 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 19 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 20 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 21 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 22 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 24 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 25 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 26 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 27 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 28 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 30 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 31 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 32 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 33 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 34 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 36 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 37 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 38 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 39 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 40 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 41 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 42 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 43 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

---